Downloading...
Download

Oncology

ImmunityBio: Catalyst for a New Era?ImmunityBio, Inc. is rapidly emerging as a significant force in the biotechnology sector, propelled by the success and expanding potential of its lead immunotherapy asset, ANKTIVA® (nogapendekin alfa inbakicept-pmln). The company achieved a pivotal milestone with the FDA approval of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This approval addresses a critical need and leverages ANKTIVA's unique mechanism as a first-in-class IL-15 agonist, designed to activate key immune cells and induce durable responses. Building on this success, ImmunityBio is actively pursuing global market access, submitting applications to the EMA and MHRA for potential approval in Europe and the UK by 2026. Beyond regulatory progress, ImmunityBio proactively tackles challenges in patient care, notably addressing the U.S. shortage of TICE® BCG. Through an FDA-authorized Expanded Access Program, the company supplies recombinant BCG (rBCG), providing a vital alternative source and expanding treatment access, particularly in underserved areas. This initiative supports patients and establishes a new market channel for ImmunityBio's therapies. Commercially, ANKTIVA's U.S. launch gains momentum, facilitated by a permanent J-code that simplifies billing and broadens insurance coverage, reaching over 240 million lives. ImmunityBio's strategic vision extends to other major cancer types. The company is advancing ANKTIVA's potential in non-small cell lung cancer (NSCLC) through a confirmatory Phase 3 trial with BeiGene. This collaboration follows promising Phase 2 data demonstrating ANKTIVA's ability to rescue checkpoint inhibitor activity in patients who have progressed on prior therapies, showing prolonged overall survival. This highlights ANKTIVA's broader potential as a foundational cytokine therapy capable of addressing lymphopenia and restoring immune function across various tumors. ImmunityBio's recent financial performance reflects this clinical and commercial traction, marked by a significant revenue increase driven by ANKTIVA sales and positive investor sentiment.
NASDAQ:IBRXLong
by UDIS_View
Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop. They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop. RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not. News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains. Check out my ideas on Utradea
NASDAQ:ELEVLong
by Magnus_Chimpski
Clovis Oncology CLVS Option CallsBased on my research, I think that the $3 strike price expiring July 15, with the price of $0.21 or lower is what I would pick right now. As you know, the OTM options can be profitable even if they don`t reach the strike price. If the stock moves closer to the strike price after you enter the trade, or if there is a rapid increase in Implied Volatility, you can sell the option for a profit. My personal goal is to transform $10k into $1Million from options trading. Thank you for viewing my out of the money option calls and puts ideas!
CLong
by CryptoCopyTrading
Mirati Therapeutics (NASDAQ: $MRTX) Flashes Signs Of Reversal 🚦Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
MLong
by Bullishcharts
AGEN digging through the CratesAGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from here? A lot of that might have to do with what's coming. " pipeline treatments like AGEN1777 have gained interest from some of the industry’s leading names. Bristol Myers Squibb ( BMY ) has a global exclusive license with Agenus providing up to $200 million in cash upfront. The company can also receive up to $1.36 billion if it reaches specific milestones and includes royalties upon any sales. The FDA already cleared an Investigational New Drug Application for a Phase 1 dosing with AGEN1777 alone and combined with an anti-PD-1 in solid tumors. That’s expected to begin this quarter...Balstilimab...is something that could be in focus as well. The FDA accepted a Biologics License Application for priority review. A Prescription Drug User Fee Act (PDUFA) target date was also given. December 16th will be the PDUFA date and could present an important one for the company and Balstilimab. Phase 2 data showed a response rate of 20% in PD-L1 positive tumors, an overall response rate of 15%, and a median duration of response of 15.4 months. Furthermore, Phase 2 trial results of balstilimab combined with zalifrelimab (AGEN1884) will be presented at a Mini Oral Session at the European Society for Medical Oncology Congress next month. So plenty to watch if AGEN stock is on your watch list right now. " Quote Source & Read more On AGEN: Hot Biotech Stocks That Deserve Your Attention In August 2021
NASDAQ:AGEN
by PennyStocks101
LTRN Lower Float, Light Vol, Big News Now What?LTRN is a stranger to high volume. For the last 2 quarters, it hasn't traded more than 355k shares on a GOOD day. Many days even see less than 100k shares trade. The current OS on it is 11 M suggesting the float is, at the very most, 11 million as of the last reported OS. This morning the company announced FDA news and was granted Orphan Drug Designation for its LP-184 pancreatic cancer treatment. "This orphan designation is one of many upcoming milestones that we expect to achieve for our LP-184 program in pancreatic cancer. We recently reported that LP-184 demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, within in-vivo mouse models over 8 weeks.  In comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8-week period. We are excited to advance this groundbreaking research to help patients suffering from this devastating disease where the benefits of current treatment options are very limited." - Panna Sharma, President & CEO of Lantern Pharma. Taking a look at the chart and fib retracement using recent lows and the anchor, you can see how the 786 fib line has remained a consistent pivot on the chart. It was a previous support that LTRN bounced off of. Now, over more recent weeks it has become more of a resistance with the stock now treading water during premarket trading on Aug 11. Though LTRN has broken above the 50DMA for the first time in quite a while, it was rejected during premarket trading when it tested the 200DMA level around $16. Considering all of these major areas of focus, it will be interesting to see if enough momentum is in play for any meaningful move to persist or if LTRN will fall back once again. If there's one thing that has been in the spotlight this summer it has been cancer treatment stocks. Sanofi (SNY) Acquired Translate Bio (TBIO) Bristol Myers' (BMY) Opdivo Showed Significant Growth Merck's drug gained FDA approval CYTK broke out big sparking a biotech rally Fate Therapeutics Progressed with its trial You also had a bunch of momentum building off the back of biotech breakouts, in general this week. "a few former penny stocks on Robinhood raised eyebrows in the analyst community. In fact, these analysts have given targets between 23% and 368% higher than where these stocks currently trade." Quote Source & Read more: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%
NASDAQ:LTRN
by PennyStocks101
CLVS 786 Fib Line Holding (For Now)Took the chart back out to March of last year to do a little fib retracement. Wouldn't you know, CLVS has been channel bound for a minute between the 618 and 786 fib lines with pretty clear support and resistance levels at each. Since it retraced back to the 786 again and is holding (for now), volume is likely going to be the "friend" or "foe" depending on how you're looking to trade this stock. You've also got the 50DMA to keep track of, which has also been a decent level of resistance over the past week or so. Fundamentally, I'm looking to see if speculation starts building later down the line after they announced that they initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in patients with FAP-positive solid tumors which is now enrolling. Either way, cancer stocks seem to be picking up some steam . Whether it's targeted treatments or drug delivery technology, oncology is beginning to take its own slice of biotech lately.
C
by PennyStocks101
ONTX Onconova Therapeutics good results = good growthThere’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price going, at present, to position himself about a 15% below. In addition, there has been a reverse split of stocks that reduces the number of shares outstanding, so the value of each individual share should increase significantly. The advisor Marketmiracle has in fact emitted a signal LONG on the Stock to the price of 6,64 usd with a target of 622 usd that is a vertical takeoff of 9268% identifying a massive entry of capitals and of interest LONG on the Stock from some great investor. Let’s just stay grounded and figure it out on the graph. The graph tells us that surely the title has the ability to climb without virtually obstacles to the resistance indicated, we see them further signs and we will reason whether the great climb should continue or not. A greater interest in biotechs and pharmaceuticals that for some time had been put aside gives us more reason to believe that the increase in price can actually take place ( see related ideas ) This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
OLong
by MarketMiracleAdvisor
7
BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimismBerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal. Sponsored analyst summary: www.trinitydelta.org Twitter: twitter.com Investor Relations: www.bergenbio.com
OSL:BGBIOLong
by savepiginvest
$ZIOPZiopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s rapid personalized manufacturing to produce and release CAR-T within two days of gene transfer. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
ZLong
by st0nkz
#IMMU look at Risk vs. Reward #VolatilitywatchThis trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line. From current stock price, potential risk/reward around 3.5 : 1 downside risk: $1.39 upside reward: $3.50-$5 Recent selloff after earnings showed strong support at the $11.59 level, which also made a double bottom. This selloff started around July, 2018. to emphasize the double bottom even more, the pullback from peak to trough retraced .618; a key level of Fibonacci support. MACD indicator showing strong convergence with price Price above 20 day moving average. 5-day exponential moving average above 20 day moving average, indicating strength in trend. Conclusion: $IMMU seems to bring opportunistic risk/ reward to investors who are sidelined. Double bottoms are significant patterns when looking for price reversal. Tip # 11: Some investors wait to buy until after stock price crosses above moving averages such as the 20, 50, 100, and 200 day. These are key phycological levels to watch when trading and investing. Like and follow so I can continue giving trend analysis and trade ideas. Thank you in advance =) Follow me on twitter or Instagram @Volatilitywatch Disclosure: I do not own IMMU. This is not a note to buy or sell. Please do your homework before investing.
ILong
by follow_the_money
$NANO.OL Breakout watch Nordic Nanovector 177Lu biotechNordic Nanovector $NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016. Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his team. Nordic Nanovector Q3 2018 and ASH 2018 abstract presentation transcript nanoinvestors.wordpress.com Novartis higlights 177Lu isotope for use in oncology radiopharmaceuticals nanoinvestors.wordpress.com Betalutin FDA Fast Track Status nanoinvestors.wordpress.com Betalutin Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma. nanoinvestors.wordpress.com Nordic Nanovector Comprehensive Company Presentation Updated October 2018 nanoinvestors.wordpress.com Nordic Nanovector mentioned by analyst ABG Sundal Collier as likely object of M&A interest nanoinvestors.wordpress.com Nordic Nanovector Analyst Coverage nanoinvestors.wordpress.com
NLong
by savepiginvest